News
Government and Business Representatives Discuss the Future of the Russian Pharmaceutical Industry
4 June 2020
Government and Business Representatives Discuss the Future of the Russian Pharmaceutical Industry
Online business breakfast ‘Challenges the State and the Pharmaceutical Industry Face Today’ took place on 2 June 2020 at 10:00. The Roscongress Foundation and The Content Foundation for the Development of Expert and Analytical Activity organized the event.
In the context of the coronavirus pandemic, the Roscongress Foundation carried on the tradition and held a business breakfast with representatives of government, community and the pharmaceutical industry in a new online format on the traditional days of the SPIEF. The Subcommittee on the Circulation of Medicinal Products and the Development of the Pharmaceutical and Medical Industry of the State Duma Committee on Health Protection supported the event and CDA became the organizational partner.
The event was attended by the Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Alla Samoylova, Director of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation Elena Maksimkina, Head of the Federal Service for Intellectual Property Grigory Ivliev, General Manager of Merck Biopharma Russia and CIS Matthias Wernicke, as well as representatives of the pharmaceutical industry. Aleksandr Petrov, Deputy, Member of the Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection moderated the business breakfast.
The event discussed strategies applied both within the pharmaceutical industry and relevant government departments and authorities in response to the challenges of the coronavirus pandemic. The business breakfast participants talked about the state support measures for the pharmaceutical industry, localization of production as a strategy to ensure uninterrupted supply of medicines, ways to simplify the drugs registration procedures and introduction into clinical practice. As an advanced measure, the Federal Service for Intellectual Property (Rospatent) announced the coming up establishment of a unified Eurasian register of pharmacologically active substances.
“It is important for us not only to guarantee patent protection to all inventors and patent holders, but we also need effective tools of such protection. Therefore, I hope that a unified Eurasian registry will be created in the near future to be maintained by Rospatent and the Ministry of Health. The copyright holder will receive the right to provide rights records to be entered in the Register. This would allow correlating it with the information on previously registered drugs and patents, and, based on this, determine the marketability of newly registered substances. The Register is also intended to aid the fight against coronavirus as it is to ensure the quick launch of newly discovered drugs and test systems, as well as protect the rights of patent holders,” commented Head of the Service Grigory Ivliev.
The event participants noted how the pharmaceutical market players and public authorities engaged in a productive dialogue and maintained communication, which became an essential ground for success during the pandemic. “Both parties are looking forward to the continuation of such a dialogue. Market participants and government officials agreed on the need to consolidate the best practices of cooperation gained during the pandemic and to expand it in the post-crisis period,” First Deputy Director for Development, and Head of Healthcare Projects Directorate at the Roscongress Foundation Anastasia Stolkova said.
Online business breakfast ‘Challenges the State and the Pharmaceutical Industry Face Today’ took place on 2 June 2020 at 10:00. The Roscongress Foundation and The Content Foundation for the Development of Expert and Analytical Activity organized the event.
In the context of the coronavirus pandemic, the Roscongress Foundation carried on the tradition and held a business breakfast with representatives of government, community and the pharmaceutical industry in a new online format on the traditional days of the SPIEF. The Subcommittee on the Circulation of Medicinal Products and the Development of the Pharmaceutical and Medical Industry of the State Duma Committee on Health Protection supported the event and CDA became the organizational partner.
The event was attended by the Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Alla Samoylova, Director of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation Elena Maksimkina, Head of the Federal Service for Intellectual Property Grigory Ivliev, General Manager of Merck Biopharma Russia and CIS Matthias Wernicke, as well as representatives of the pharmaceutical industry. Aleksandr Petrov, Deputy, Member of the Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection moderated the business breakfast.
The event discussed strategies applied both within the pharmaceutical industry and relevant government departments and authorities in response to the challenges of the coronavirus pandemic. The business breakfast participants talked about the state support measures for the pharmaceutical industry, localization of production as a strategy to ensure uninterrupted supply of medicines, ways to simplify the drugs registration procedures and introduction into clinical practice. As an advanced measure, the Federal Service for Intellectual Property (Rospatent) announced the coming up establishment of a unified Eurasian register of pharmacologically active substances.
“It is important for us not only to guarantee patent protection to all inventors and patent holders, but we also need effective tools of such protection. Therefore, I hope that a unified Eurasian registry will be created in the near future to be maintained by Rospatent and the Ministry of Health. The copyright holder will receive the right to provide rights records to be entered in the Register. This would allow correlating it with the information on previously registered drugs and patents, and, based on this, determine the marketability of newly registered substances. The Register is also intended to aid the fight against coronavirus as it is to ensure the quick launch of newly discovered drugs and test systems, as well as protect the rights of patent holders,” commented Head of the Service Grigory Ivliev.
The event participants noted how the pharmaceutical market players and public authorities engaged in a productive dialogue and maintained communication, which became an essential ground for success during the pandemic. “Both parties are looking forward to the continuation of such a dialogue. Market participants and government officials agreed on the need to consolidate the best practices of cooperation gained during the pandemic and to expand it in the post-crisis period,” First Deputy Director for Development, and Head of Healthcare Projects Directorate at the Roscongress Foundation Anastasia Stolkova said.